help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2005-0683
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, R. A
Right arrow Articles by Risbridger, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, R. A
Right arrow Articles by Risbridger, G. P.
Endocrinology Vol. 147, No. 1 191-200
Copyright © 2006 by The Endocrine Society

17ß-Estradiol Induces Apoptosis in the Developing Rodent Prostate Independently of ER{alpha} or ERß

R. A Taylor, P. Cowin, J. F. Couse, K. S. Korach and G. P. Risbridger

Monash Institute of Reproduction and Development (R.A.T., P.C., G.P.R.), Monash University, Clayton, Victoria 3168, Australia; Department of Environmental and Molecular Toxicology (J.F.C.), North Carolina State University, Raleigh, North Carolina 27695; and Receptor Biology Section (J.F.C., K.S.K.), Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences/National Institutes of Health, Research Triangle Park, North Carolina 27709

Address all correspondence and requests for reprints to: Professor Gail P. Risbridger, Monash Institute of Medical Research, Monash University, 27–31 Wright Street, Clayton, Victoria 3168, Australia. E-mail: gail.risbridger{at}med.monash.edu.au.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Estrogens induce both proliferative and antiproliferative responses in the prostate gland. To date, antiproliferative effects of estrogens are generally considered to be due to systemic antiandrogenic actions. However, estrogen action mediated through estrogen receptor (ER) ß was recently suggested as another mechanism of induction of apoptosis in the prostate. This study aimed to explore the hypothesis that the antiproliferative effects of estrogen are directly mediated through ERß using a prostate organ culture system. We previously reported effects of 17ß-estradiol (E2) using rat ventral prostate (VP) tissues, and adapted the system for culturing mouse tissues. In both rat and mouse models, estrogen-induced apoptosis was detected that was spatially and regionally localized to the epithelium of the distal tips. Using organ cultures of {alpha}ER knockout ({alpha}ERKO) and ßERKO prostates, we failed to demonstrate that apoptosis induced by E2 was mediated through either receptor subtype. Activation of ER-selective ligands (ER{alpha}, propyl pyrazole triol, ERß, diaryl-proprionitrile, and 5{alpha}-androstane-3ß,17ß-diol) in organ culture experiments failed to induce apoptosis, as did the membrane impermeable conjugate E2:BSA, discounting the possibility of nongenomic effects. Consequently, E2 regulation of androgen receptor (AR) expression was examined and, in the presence of nanomolar testosterone levels, E2 caused a specific reduction in AR protein expression in wild-type, {alpha}ERKO, and ßERKO mice, particularly in the distal region where apoptosis was detected. This down-regulation of AR protein provides a possible mechanism for the proapoptotic action of E2 that is independent of ERs or nongenomic effects.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
HIGH DOSES OF estrogens inhibit prostate growth both in vivo and in vitro. However, in vivo experiments are complicated by the fact that estrogens exert indirect effects on the prostate, by negative feedback on the hypothalamic-pituitary gonadal axis, thereby suppressing androgen production. Any reduction in androgen levels, androgen receptor (AR) expression, or androgen signaling will result in atrophy, decreased secretory activity, and apoptosis in the epithelium (1). In addition to indirect effects of estrogen in modulating androgen production, estrogens also have direct effects on the prostate itself. Evidence that estrogens act directly upon the prostate is implied because the estrogen receptors (ERs) {alpha} and ß reside within the gland. The expression of the ERs has been described in the developing and adult prostate and they are differentially localized; ER{alpha} is predominantly found in the stroma (2, 3), although it can be detected in the epithelium after estrogen exposure (4), and ERß is predominantly found in the epithelium (3, 5, 6).

Estrogens induce both proliferative and antiproliferative effects in the prostate. Several studies have identified that ER{alpha} is responsible for mediating proliferative actions by estrogens on the prostate during development and adulthood (4, 5). A previous study by Prins et al. (5) used {alpha}ER knockout ({alpha}ERKO) and ßERKO mice to demonstrate that ER{alpha} was the dominant ER form mediating developmental estrogenization of the prostate gland. Squamous metaplasia is another biological response induced by exogenous estrogen exposure that is mediated via ER{alpha} as demonstrated by tissue recombination studies (4).

Although ERß is the predominant epithelial ER residing in the prostate, a biological endpoint mediated through this receptor remains to be defined. It was postulated that direct antiproliferative effects of estrogens in the prostate are mediated through ERß (7, 8, 9, 10). This hypothesis is based on several lines of correlative evidence. Firstly, mice deficient in ERß (ßERKO) were reported to demonstrate foci of epithelial prostate hyperplasia upon aging that was associated with higher proliferative and lower apoptotic indexes (8, 9, 10), although this phenotype was not confirmed by other laboratories (5, 11, 12). Secondly, administration of antiestrogens (tamoxifen and ICI 182,780) to the human prostate cancer cell line, DU145, which express only ERß, and not ER{alpha}, caused growth inhibition (13) and cotreatment of DU145 cells with ERß-antisense oligonucleotide reversed the antiproliferative effects induce by ICI 182,780 (13), suggesting that ERß mediated growth-inhibitory actions of antiestrogens in tumor cells. Thirdly, ERß binds to electrophile/antioxidant response elements that stimulate induction of genes such as quinone reductase and gluthanthione S-transferase that are protective against carcinogenesis (14). Although these associated data infer antiproliferative actions mediated by ERß, direct evidence is not available.

The problem with demonstrating that ERß induces antiproliferative or proapoptotic responses relates to the exquisite sensitivity of the prostate to changes in androgens, or androgen signaling, associated with estrogen administration in vivo. Therefore, to circumvent the centrally mediated effects of estrogens in decreasing serum androgen levels, we have developed an organ culture system where prostate lobes are grown in a defined hormonal environment, so that androgen levels are maintained, and direct effects of estrogens can be examined. We previously used this system using rat ventral prostate (VP) lobes (15). Here we report for the first time that this organ culture model can be adapted to allow maintenance of mouse prostate lobes in vitro, thereby permitting the use of genetically altered mouse models in such experiments. In this study, we have used ER gene-targeted models ({alpha}ERKO and ßERKO mice) to study the specific role of each receptor subtype in mediating antiproliferative effects of estrogen on the developing prostate. In addition, we have adapted a complementary, alternative approach using several ER subtype-selective ligands to delineate ER-mediated events. The aim of this study was to test the hypothesis that ERß activation directly mediates apoptotic effects in the developing rodent prostate, independent of regulation of androgen levels.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals and tissue collection
All animal handling and procedures were carried out in accordance with National Health and Medical Research Council guidelines for the Care and Use of Laboratory Animal Act and according to the Animal Experimentation and Ethics Committee at Monash Medical Centre (Clayton, Australia). Sprague Dawley outbred rats (d 0), ({alpha}ERKO [C57BL/6J black mice (16)], ßERKO [C57BL/6J black mice (17)] and normal C57BL/J6 mice were killed on d 1–2 after birth. VP lobes were microdissected for organ culture.

Organ culture
Organ culture was carried out as previously described in rat (15, 18), although there were some modifications to satisfy mouse organ culture conditions. Pilot studies in C57BL/6J mice demonstrated that mice needed to be at least postnatal d 1 (weight range 1.5–2.0 g) to undergo normal branching morphogenesis (data not shown). Briefly, all animals from each litter ({alpha}ERKO and ßERKO colonies) were cultured blind because the genotypes were unknown at the beginning of the culture. Mice were killed by decapitation and tail snips collected from each of the KO mice for genotyping.

Tissue collection for mouse and rat tissues involved microdissection of VPs (rat lobes collected independently and mouse lobes collected as two lobes together). Each explant was cultured on Millicell CM filters (Millipore Corp., Bedford, MA) floating on 500 µl of nutrient media in a four-well plate at 37 C in a humidified 5% CO2 incubator. A basal medium of DMEM/Ham’s F-12, 1:1 (vol/vol) lacking phenol red, supplemented with insulin (10 µg/ml) and transferrin (10 µg/ml) was used in all experimental groups. The medium was supplemented with 10 nM testosterone (T), and treatment groups were cultured with high doses of 17ß-estradiol (E2; 15 µM) together with 10 nM T or E2 alone. Other estrogenic compounds were tested including 3ßAdiol (5{alpha}-androstane-3ß,17ß-diol; putative ERß ligand), E2:BSA (Sigma-Aldrich, St. Louis, MO), an ER{alpha}-selective ligand [1,35-(4-hydroxyphenyl)-4-propyl-1H pyrazole; propyl pyrazole triol; PPT]; Tocris Cookson Ltd., Avonmouth, UK), and an ERß-selective ligand [2,3-bis-(4-hydroxyphenyl)-propionitrile; diaryl-propionitrile; DPN; Tocris]. Steroids were tested at a range of doses (10–5 M to 10–13 M) and vehicle controls were conducted. At least four explants of each genotype were subjected to each hormonal treatment.

The organs were harvested after 5 d of culture. Explants were photographed, fixed in Bouins fixative for 1 h at room temperature, and then processed to paraffin for histological and stereological analysis.

Histology
Fixed tissues were processed and embedded in paraffin for histological analysis. Care was taken to ensure tissues were embedded so that longitudinal sections could be obtained. Serial 5-µm sections were cut on a microtome and dried onto Superfrost Plus+ slides (Menzel-Glazer, Braunschweig, Germany) before histological and stereological examination. Hematoxylin and eosin (H&E) staining was performed on every fifth section to examine the pathology throughout the whole tissue.

Detection of apoptosis
Apoptosis was analyzed by ApopTag In Situ Apoptosis Detection Kit (Integren, Purchase, NY). Briefly, sections were dewaxed, incubated in Equilibration Buffer (Intergren), then treated with TdT enzyme in Reaction Buffer (Integren) for 1 h at 37 C. Sections were washed in Stop Wash Buffer (Integren) for 30 min at 37 C, treated with 3% (vol/vol) H2O2 in methanol for 15 min, and blocked with CAS block (Zymed Laboratories Inc., South San Francisco, CA). Apoptotic cells were detected by antidigoxigenin conjugate (Integren) for 30 min at room temperature and color reacted with 3,3'-diaminobenzidine tetrahydrochloride (liquid substrate kit; Zymed). The reactions were stopped with water and sections were counterstained with Mayer’s hematoxylin, dehydrated, cleared and mounted.

Immunohistochemistry
Immunolocalization of AR and ERs {alpha} (ER{alpha}) and ß (ERß) was detected using the Dako Autostainer Universal Staining System (Dako A/S, Carpinteria, CA). Immunostaining was conducted on n = 3 animals from each group, including n = 10 sections (i.e. every fifth or sixth section, depending on the tissue size) from each tissue to sample throughout the explant. Immunoreactivity for AR, ER{alpha}, and ERß was detected after sections were subjected to microwave antigen retrieval in 0.01 M citrate buffer (pH 6.0), boiling for 20 min. Antigen retrieval for caspase-3 immunoreactivity was carried out in 0.01 M sodium citrate buffer (pH 6.0), boiling for 10 min. All sections were then treated with peroxidase blocking reagent (Dako Envision System kit; Dako) for 30 min, and nonspecific binding was blocked using CAS block for at least 30 min (Zymed). Monoclonal antibody AR (N-20) (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a working concentration of 0.33 µg/ml or concentration-matched rabbit IgG (Dako) for 1 h at room temperature. Monoclonal ER{alpha} (1D5) (Dako Corp., Carpinteria, CA) and monoclonal antibody ERß (NCL-ER-ß) (Novocastra Laboratories Ltd., UK) at working concentrations of 14 µg/ml and 1 µg/ml, respectively, for 2 h at room temperature. Polyclonal antibody cleaved caspase-3 (Asp175) (Cell Signaling Technology, Inc., Beverly, MA) at a working concentration of 1 µg/ml for 2 h at room temperature. Antibodies were detected by incubation with peroxidase-labeled polymer (Dako Envision System; Dako), which is conjugated to antimouse and antirabbit Igs, for 15 min at room temperature and then color reacted with 3,3'-diaminobenzidine tetrahydrochloride (liquid substrate kit) for 5 min. The reactions were stopped in water, and sections were counterstained with Mayer’s hematoxylin, dehydrated, cleared, and mounted.

Semiquantitation of apoptosis
The incidence of apoptosis was estimated based on a method that allowed an unbiased semiquantitation of the percentage of apoptotic cells in both treated and control samples (19). Tissue sections were mapped at x40 magnification to define tissue boundaries. Random fields were systematically selected by computer-assisted software: CAST version 1.10 software (Computer Assisted Stereological Toolbox) (Olympus Danmark A/S, Albertslund, Denmark), and sampling was conducted using a three-by-two unbiased counting frame. Frame counting was performed on 10 sections uniformly spaced throughout the tissue, n = 3 for each group, with an average of 1500 cells counted per section. Cells were classified as either apoptotic or nonapoptotic-based on Apoptag labeling (only fully stained apoptotic cells that exhibited histological characteristics typical of cells undergoing programmed cell death were counted as positive, thereby avoiding counts of end stage apoptotic bodies) and represented as percentage of total cells. All data were expressed as the mean ± SEM. Control and treatment groups were compared using a two-tailed paired t test, with the significance threshold employed at a level of 5% (P < 0.05). All data analyses were conducted using Prism 2.01 software (GraphPad Software, Inc., San Diego, CA).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Effect of E2 on rat prostate development in vitro
Organ culture of rat VP in the presence of T (10 nM) has been described previously (15), mimicking in vivo development in vitro (Fig. 1AGo). In addition, we previously demonstrated that culture of neonatal rat VPs in the presence of T plus E2 (15 µM) retards growth and reduces the extent of branching morphogenesis (15) (Fig. 1BGo). Administration of T plus E2 to neonatal rat VPs in vitro altered stromal cell differentiation, particularly smooth muscle development, as well as perturbed epithelial differentiation (15). Figure 1Go, C and D, shows that, in explants of rat VP, reduced growth is associated with an increase in the incidence of apoptosis in organs cultured in the presence of T plus E2, compared with T alone, as detected by ApopTag labeling. The incidence of apoptosis was very low in media containing T alone (Fig. 1CGo), but in the presence of T plus E2, there was a significant increase in the incidence of apoptosis that was predominantly found in the differentiating epithelial cells of the distal region, where branching morphogenesis and epithelial cord formation occurs (Fig. 1DGo). The incidence of apoptosis was confirmed using a second detection technique, specifically immunolocalization of cleaved caspase-3 (one of the key executioners of apoptotic pathway). Using this approach, a similar incidence of apoptosis was observed after T alone and T plus E2 (data not shown). The incidence of apoptosis was estimated using a semiquantitation technique, which revealed an approximately 8-fold increase in the percentage of cells undergoing apoptosis after T plus E2 (5.25 ± 0.17%) treatment compared with T alone (0.65 ± 0.03%; Table 1Go).



View larger version (120K):
[in this window]
[in a new window]
  		FIG. 1. Culture of rat VPs in organ culture model. Whole mount photomicrographs of explants after organ culture in the presence of T alone (A) and T plus E2 (B). ApopTag immunolabeling of cells undergoing apoptosis after culture in the presence of T alone (C) and T plus E2 (D). Arrow (->) highlights cells in apoptosis. Bar, 500 µm (A and B); 25 µm (C and D).

 

View this table:
[in this window]
[in a new window]
  		TABLE 1. Incidence of apoptosis after organ culture in the presence of T and T plus E2 in rat and mouse (including wt, {alpha}ERKO, and ßERKO mice) ventral prostates

 
Establishment of mouse VP organ culture; comparison to in vivo tissues
To perform experiments using genetically altered mice, we adapted the organ culture technique for mouse prostate and report here in vitro development of mouse VPs for the first time. Specifically, we used older mouse tissues (d 1–2 postnatal rather than day of birth), and cultured paired organs connected by shared mesenchyme, rather than isolated lobes. Using these regimes, we were able to maintain the integrity of the glands for up to 5 d of culture and the development of explants cultured in vitro was similar to that observed in age-matched in vivo tissues (Fig. 2Go, A–J). Tissues were isolated on d 1 after birth, and each VP lobe consisted of two main ducts that had initiated branching (Fig. 2AGo). A histological section of these tissues revealed undifferentiated epithelial cords invading the surrounding mesenchyme (Fig. 2BGo). To confirm that the development we observed in vitro mimicked that observed in vivo, we isolated mouse VP lobes from postnatal d 4 (Fig. 2CGo) and 8 (Fig. 2DGo). Over the first 6–8 d in vivo, mouse VPs undergo extensive growth and significant branching morphogenesis occurs (Fig. 2Go, C and D). Histologically, postnatal d 8 VPs exhibit proximal to distal maturation of the ducts with some canalization and maturation in the proximal region, whereas the distal tips remain undifferentiated and continue budding into the surrounding mesenchyme (Fig. 2EGo). There is little lumen formation at the stage of development. By comparison, mouse VPs that were isolated at d 1–2 (Fig. 2Go, A and B) were maintained in vitro in the presence of T alone for 5–6 d (equivalent of in vivo d 8) and underwent similar development involving branching morphogenesis and ductal formation (Fig. 2Go, F and G). The main difference between these in vitro explants and the equivalent in vivo tissues is architecture of the lobes; in vivo tissues maintain three-dimensional structure, whereas the in vitro explants tend to grow in a flattened manner, generating a more two-dimensional shape. Nonetheless, histological analysis of the in vitro explants revealed similar maturation and differentiation to comparative in vivo explants, although more advanced canalization and lumen formation (Fig. 2HGo). Differentiation and organization occurred in a proximal to distal manner, with the most advanced development observed in the proximal region and newly forming ductal structures in the distal region (Fig. 2Go, I and J). In the proximal region, the epithelium became polarized and secretory epithelial cells were observed in addition to the underlying basal cells (Fig. 2IGo), whereas the epithelium was actively differentiating and proliferating in the distal tips (Fig. 2JGo).



View larger version (60K):
[in this window]
[in a new window]
  		FIG. 2. Comparison of in vivo and in vitro mouse VP development. A, Whole mount photomicrograph of d 1 postnatal mouse VP lobes. B, H&E of d 1 postnatal mouse VP lobes. Whole mount photomicrographs of intact mouse VP lobes collected at d 4 (C) and d 8 (D) postnatal. E, H&E of d 8 mouse ventral prostate. Whole mount photomicrographs of mouse VPs after culture in the presence of T after 3 d (F) and 5 d (G) in vitro. H, H&E of d 5 mouse VPs after culture in the presence of T, proximal region (I), and distal region (J). Bar, 125 µm (A, C, D, F, and G); 50 µm (B, E, and H); and 25 µm (I and J).

 
Effect of E2 on wild-type (WT) mouse VP growth in vitro
In the presence of 10 nM T, the growth inhibitory effects of E2 were dose responsive over a concentration range 10 nM to 20 µM (Fig. 3Go, A–F), consistent with previous observations (15). High E2 concentrations (micromolar) significantly reduced prostate growth, whereas lower concentrations (nanomolar) reduced the inhibitory effect such that explants were not significantly different from control explants. Similar to previous studies in rat VPs (15), a concentration of 15 µM was chosen to further investigate the mechanism of estrogen-induced apoptosis in the mouse VP.



View larger version (102K):
[in this window]
[in a new window]
  		FIG. 3. Dose response of E2 in the presence of 10 nM T on mouse VP organ cultures. Explants were cultured in the presence of T alone (A), T plus 10 nM E2 (B), T plus 1 µM E2 (C), T plus 10 µM E2 (D), T plus 15 µM E2 (E), and T plus 20 µM E2 (F). Bar, 125 µm.

 
Mouse VPs from WT mice were cultured in the presence of T alone (10 nM) and normal growth was observed in vitro, as described above (Fig. 4AGo). When cultured in the presence of T plus E2 (15 µM), branching morphogenesis was reduced (Fig. 4BGo) so that there were generally fewer secondary and terminal branches; the main branches were elongated and distended, rather than forming new branches. In some regions, these ducts were dilated and cystic (Fig. 4BGo). The incidence of apoptosis in mouse VPs after culture in the presence of T alone, and T plus E2 is shown in Fig. 4Go, C–F. An examination of proximal and distal regions revealed very few apoptotic cells after culture in the presence of T alone (Fig. 4CGo). In contrast, treatment with T plus E2 induced a significant amount of apoptosis that was specifically in the epithelium of the distal tips (Fig. 4DGo). These observations in the WT mouse were similar to the responses observed in the rat VP organ cultures (Fig. 1Go). Interestingly, apoptotic cells were noted adjacent to cells actively undergoing mitosis, indicating that proliferation was concurrent with cell death (Fig. 4Go, C and D). The incidence of apoptosis was confirmed using immunolocalization of cleaved caspase-3 and using this approach, a similar incidence of apoptosis was observed after T alone (Fig. 4EGo) and T plus E2 (Fig. 4FGo). Semiquantitation revealed a significant increase in the percentage of cells undergoing apoptosis in the mouse VPs, at similar levels to that observed in the rat tissues (T alone, 0.54 ± 0.13% vs. T plus E2, 5.10 ± 1.13%; Table 1Go).



View larger version (133K):
[in this window]
[in a new window]
  		FIG. 4. Culture of mouse VPs after T plus E2 treatment and incidence of apoptosis. WT mouse VP after 5 d of culture in the presence of T (C) and T plus E2 (D). Photomicrographs demonstrating the incidence of apoptosis in WT mouse VPs after 5 d of culture in the presence of T (C) and T plus E2 (D). Immunolocalization of cleaved caspase-3 in WT mouse VPs after 5 d of culture in the presence of T (E) and T plus E2 (F); insets for C–F demonstrate high power images of epithelial cells undergoing apoptosis. Arrow (->) highlights cells in apoptosis, *, Dividing cells. Bar, 125 µm (A and B); 25 µm (C–F); and 10 µm (C–F, insets).

 
Localization of ERs
After culture in the presence of T alone, regional variation in the expression of ERs was observed. ER{alpha} immunostaining was restricted to individual cells within the proximal region, specifically in mesenchymal cells (Fig. 5Go, A and B). In contrast to ER{alpha} immunoreactivity, ERß immunoreactivity was observed in both the proximal and distal regions. Proximally, nuclear ERß staining was localized to smooth muscle, stromal and epithelial cell types (Fig. 5CGo). Comparatively, in the distal region ERß immunoreactivity was predominantly localized to the smooth muscle and stromal cells; however, weak basal epithelial cell staining was apparent (Fig. 5DGo). After 5 d of culture in the presence of T plus E2, immunolocalization of ER{alpha} was down-regulated so that it was low/undetectable in both proximal and distal regions (Fig. 5EGo), whereas ERß was up-regulated, particularly in the epithelial cells in the distal regions of the gland (Fig. 5FGo), where the majority of apoptotic cells were observed. There was no apparent difference in stromal cell expression of ERß throughout the gland when compared with T-treated controls after E2 treatment. This apparent increase in ERß, together with the concurrent expression in the region where cells were undergoing apoptosis, further supported the idea that estrogen-induced apoptosis may be mediated through this receptor. Therefore, this hypothesis was tested in ERKO mouse VPs.



View larger version (138K):
[in this window]
[in a new window]
  		FIG. 5. Immunolocalization of ER{alpha} and ERß mouse VPs after organ culture in the presence of T alone (A–D) and T plus E2 (E and F). Localization of each receptor was variable between the proximal (A, B, E, and F) and distal (C and D) region of the explants. Bar, 25 µm in all photomicrographs.

 
Effect of E2 on {alpha}ERKO and ßERKO mouse VP growth in vitro
After 5 d of culture with T alone, {alpha}ERKO and ßERKO VPs had apparently normal branching morphogenesis and no gross abnormalities were observed (Fig. 6Go, A and B). In the presence of T alone, {alpha}ERKO and ßERKO mouse VPs showed a very low incidence of apoptosis throughout, after examination of proximal and distal regions (Fig. 6Go, C and D; and Table 1Go), similar to WT. After culture in the presence of T plus E2, {alpha}ERKO and ßERKO VPs responded similar to WT mice, with reduced branching and distended duct formation (Fig. 6Go, E and F). In {alpha}ERKO mice, growth was more reminiscent of explants cultured with T alone, although some regions still had ducts that were dilated and cystic (Fig. 6EGo). However, in the presence of T plus E2, both {alpha}ERKO and ßERKO mice exhibited a significant increase in the incidence of apoptosis, particularly in the distal epithelial tips (Fig. 6Go, G and H), indicating that estrogen-induced apoptosis still occurred in the absence of functional ER{alpha} or ERß. This increase in apoptosis in {alpha}ERKO and ßERKO mouse VPs after T plus E2 treatment was confirmed by immunolocalization of cleaved caspase-3 (data not shown) and semiquantitation (Table 1Go).



View larger version (82K):
[in this window]
[in a new window]
  		FIG. 6. Culture of {alpha}ERKO and ßERKO mouse VPs in organ culture model. Whole mount photomicrograph of explants after 5 d of culture in the presence of T in {alpha}ERKO (A) and ßERKO (B) mice. Photomicrographs demonstrating the incidence of apoptosis in {alpha}ERKO (C) and ßERKO (D) VPs after culture in the presence of T alone. Whole mount photomicrograph of explants after 5 d of culture in the presence of T plus E2 in {alpha}ERKO (E) and ßERKO mice (F). Photomicrographs demonstrating the incidence of apoptosis in {alpha}ERKO (G) and ßERKO (H) VPs after culture in the presence of T plus E2; insets for G and H demonstrate high power images of epithelial cells undergoing apoptosis. Arrow (->) highlights cells in apoptosis. Bar, 125 µm (A, B, E, and F); 25 µm (C, D, G, and H); and 10 µm (G and H, insets).

 
Effect of ER{alpha}- and ERß-selective ligands on mouse prostate development in vitro
To confirm whether estrogen-induced apoptosis was mediated through either ER{alpha} or ERß, we investigated the biological response to ER{alpha}- and ERß-selective ligands on mouse prostate development. WT C57BL/J6 mice were used for this study. To validate the use of the subtype-specific ER ligands, vehicle only controls were conducted and explants were similar to T-treated explants (data not shown). In the presence of T alone, explants developed similar to that observed in vivo, and extensive branching morphogenesis occurred (Fig. 7AGo). Histologically, the epithelium became polarized and secretory epithelial cells were observed in addition to the underlying basal cells, concurrent with differentiation and organization of the surrounding stromal tissue (Fig. 7BGo). The incidence of apoptosis was low, consistent with previous observations (Fig. 7CGo).



View larger version (89K):
[in this window]
[in a new window]
  		FIG. 7. Culture of C57BL/J6 mice in the presence of ER-specific agonists. Whole mount photomicrograph of explants after 5 d of culture in the presence of T (A), T plus PPT (10–5 M) (D), and T plus DPN (10–5 M) (G). H&E photomicrographs of mouse VPs after 5 d of culture in the presence of T (B), T plus PPT (10–5 M) (E), and T plus DPN (10–5 M) (H). Photomicrographs demonstrating the incidence of apoptosis after 5 d of culture in the presence of T (C), T plus PPT (10–5 M) (F), and T plus DPN (10–5 M) (I). Arrow (->) highlights cells in apoptosis. Bar, 125 µm (A, D, and G) and 25 µm (B, C, E, F, H, and I).

 
When cultured in the presence of T plus an ER{alpha}-specific ligand (PPT; 10 µM), explants showed a striking reduction in growth (Fig. 7DGo). The size of the explants was significantly smaller and there was less branching morphogenesis. Concurrent with the reduction in growth of PPT-treated explants, histological examination by H&E staining revealed significant morphological alterations with ductal branching, elongation and canalization interrupted throughout the entire gland (Fig. 7EGo). The spatial and regional organization was not apparent, and the ductal architecture was severely altered. Similar to T-treated controls, the incidence of apoptosis was also low because very few cells were detected by ApopTag labeling (Fig. 7FGo) or immunolocalization of cleaved caspase-3 (data not shown).

After 5 d of culture with T plus an ERß-specific ligand (DPN; 10 µM), mouse VPs were larger than explants treated with T alone (Fig. 7GGo). This enlargement appeared to be the result of excessive dilation of the ducts that may be associated with increased production of secretory products. H&E examination revealed several differences in cellular morphology when compared with T-treated control explants (Fig. 7HGo). In T plus DPN-treated explants, branching morphogenesis appeared reduced with generally fewer secondary and tertiary branches. The main ductal branches appeared elongated and distended with large lumen spaces. Epithelial cell differentiation appeared well developed throughout the entire tissue, with pseudostratified columnar epithelium lining the majority of the ductal length (Fig. 7HGo). Similarly to T and T plus PPT (ER{alpha}-specific ligand)-treated explants, the incidence of apoptosis remained very low in T plus DPN (ERß-specific ligand)-treated explants (Fig. 7IGo).

Effect of 3ßAdiol on rodent prostate development in vitro
The T metabolite 3ßAdiol is reported to be a specific ligand for ERß in the prostate (9, 20). To test whether 3ßAdiol was able to induce apoptosis in the developing rodent prostate similar to E2, organ culture experiments were conducted on both rat and mouse VPs. To validate the use of 3ßAdiol, vehicle-only controls were conducted and explants were similar to T-treated explants (data not shown). Results presented represent the rat organ culture explants (Fig. 8Go, A–D), but these effects were also observed in organ cultures using C57BL/J6 mouse ventral prostate lobes (data not shown). In the presence of T, 3ßAdiol was tested at several doses (including 20 µM, 10 µM, and 1 µM), similar to the dose range required for E2 to induce apoptosis. At the highest dose (20 µM), 3ßAdiol caused little change in prostate size and growth (Fig. 8Go, A and B). The extent and pattern of branching morphogenesis was not altered and development occurred similar to explants cultured with T alone (Fig. 8AGo). In terms of apoptosis, the incidence of programmed cell death in control explants cultured with T alone was very low, with few cells immunolabeled with the ApopTag detection kit (Fig. 8CGo). Similarly, the incidence of apoptosis in explants cultured in the presence of T plus 3ßAdiol (20 µM) was also very low (Fig. 8DGo).



View larger version (110K):
[in this window]
[in a new window]
  		FIG. 8. Culture of rat VPs in the presence of 3ßAdiol and mouse VPs in the presence of E2:BSA. Whole mount photomicrographs of rat VPs after organ culture in the presence of T alone (A) and T plus 3ßAdiol (20 µM) (B). ApopTag immunolabeling of cells undergoing apoptosis after culture in the presence of T alone (C) and T plus 3ßAdiol (D). Whole mount photomicrographs of mouse VPs after organ culture in the presence of T alone (E) and T plus E2:BSA (F). ApopTag immunolabeling of cells undergoing apoptosis after culture in the presence of g. T alone (G) and T plus E2:BSA (H). Arrow (->) highlights cells in apoptosis. Bar, 500 µm (A and B), 125 µm (E and F), and 25 µm (C, D, G, and H).

 
Effect of E2:BSA on mouse prostate development in vitro
To test whether estrogen-induced apoptosis was the result of nongenomic estrogenic actions, we determined the effect of a membrane impermeable conjugate of E2, namely E2:BSA. Results presented represent the mouse C57BL/J6 organ culture explants (Fig. 8Go, E–H). In the presence of T plus E2:BSA, branching morphogenesis was similar to T-treated control explants (Fig. 8Go, E and F). In terms of apoptosis, the incidence of programmed cell death in control explants cultured with T alone was very low, with few cells immunolabeled with the ApopTag detection kit (Fig. 8GGo). Similarly, the incidence of apoptosis in explants cultured in the presence of T plus E2:BSA was also very low (Fig. 8HGo).

AR expression
Because the estrogen-induced apoptosis observed in both mouse and rat organ culture experiments was not shown to be mediated through ER{alpha} or ERß by two experimental models (using ERKO mice and ER-selective ligands), we investigated the possibility that estrogen was acting indirectly via modulation of AR expression after treatment with T alone and T plus E2. After culture in the presence of T alone, AR immunolocalization was detected in both the mesenchymal and epithelial cells throughout WT VP explants (Fig. 9Go, A and B). There was variability in AR immunostaining along the prostatic ducts within the proximal and distal regions. In the distal region, where most proliferation and differentiation occurred, AR immunostaining was strong and nearly all cells were immunopositive for AR (Fig. 9AGo). In the more differentiated proximal region, where epithelial polarization and lumen formation occurred, there were some cells, particularly in the epithelium that were immunonegative for AR (Fig. 9BGo). In contrast, culture in the presence of T plus E2 using WT mice resulted in a significant decrease in AR immunolocalization in both the distal (Fig. 9CGo) and proximal (Fig. 9DGo) regions, particularly in the epithelial cells. AR expression was still detectable in epithelial and mesenchymal cells; however, the number of cells that were immunopositive and the staining intensity were reduced (Fig. 9CGo). The decrease in the proximal region was not as significant (Fig. 9DGo) compared with the proximal region of explants treated with T alone. {alpha}ERKO and ßERKO mouse VPs treated with T alone showed comparable AR expression to WT VPs (Fig. 9Go, E and G). Similarly, {alpha}ERKO and ßERKO VPs cultured in the presence of T plus E2 also showed significant down-regulation of AR in the distal epithelium as detected by immunolocalization (Fig. 9Go, F and H).



View larger version (122K):
[in this window]
[in a new window]
  		FIG. 9. Immunlocalization of AR in WT (A–D), {alpha}ERKO (E and F) and ßERKO (G and H) VPs in the distal region of the ventral prostate (except B and D, which represent the proximal region). Photomicrographs represent explants cultured in the presence of T alone (A, B, E, and G) and T plus E2 (C, D, F, and H). Bar, 25 µm in all photomicrographs.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we have adapted a serum-free prostate organ culture technique to maintain neonatal murine tissues in culture. This system maintains stromal-epithelial interactions within the prostate, as well as allowing prostate growth in defined hormonal environments, where androgen levels can be kept constant. The adaptation of this model to allow organ culture of mouse prostate tissues expands the utility of the system to allow the use of genetically altered mouse models in such studies, in this case, {alpha}ERKO and ßERKO mice.

Here we report that the addition of high-dose E2 resulted in antiproliferative events including active induction of apoptosis in the prostate epithelium, particularly in the distal tip epithelium, where ERß was previously localized (21). Data presented here also indicated that ERß expression was increased in the distal tip epithelium after E2 treatment. However, using ERKO mice, we failed to demonstrate a specific role for ER{alpha} or ERß in mediating apoptosis because apoptosis was consistently observed after E2 exposure to prostate glands from either {alpha}ERKO or ßERKO mice. Ideally, we would prefer to test the effects of E2 in {alpha}ßERKO tissues, but because each litter only provides 1:16 double KO males, this experiment was not feasible. Instead, we adapted an alternative approach using ER-specific ligands PPT (ER{alpha}) or DPN (ERß) and 3ßAdiol (ERß) and showed these agonists were also unable to induce the apoptotic response. These data implied that apoptosis was caused by a non-receptor-mediated event or was mediated through another indirect estrogen signaling mechanism. We also tested whether the observed apoptosis was due to nongenomic effects of estrogens; however, organ culture experiments using the membrane impermeable conjugate E2:BSA failed to demonstrate an effect.

However, subsequent data revealed a down-regulation of AR, which may provide an alternative explanation for the observed apoptosis in the prostate. AR regulation was independent of androgen levels because T was maintained in the culture media, suggesting there was direct modulation of AR protein expression by E2. Our data suggested that AR down-regulation occurred independently of either ER subtypes because the effect is observed in {alpha}ERKO and ßERKO prostates. We did not quantitate the decrease in AR protein by Western analysis because examination of whole tissue homogenates would mask the changes in cell-specific expression; using immunohistochemistry we observed a marked loss of epithelial AR. The induction of epithelial cell apoptosis by castration (androgen removal) has been well documented (22, 23) and tissue recombination studies eloquently demonstrated that this epithelial response is a paracrine event mediated through the loss of stromal ARs, rather than reduced stimulation of epithelial ARs (24). However, in this study we observed a predominant loss of epithelial AR, rather than stromal AR and so it is not convincing that loss of AR protein is the only factor involved in the apoptotic response.

Nonetheless, the regulation of AR protein expression by estrogen is important to consider. Pharmacological doses of estrogen have been shown in multiple systems, including the one presented here, to decrease AR levels (5, 9, 10, 25) although the mechanism by which this occurs is not well understood. Prins et al. (5) described altered AR protein expression by estrogens that was mediated through ER{alpha} and partially ERß, using an in vivo treatment regime. Further studies by the same group have indicated that estrogen alters AR expression posttranscriptionally (via protein degradation), whereas AR mRNA levels may be unaltered (26). Another suggestion by Weihua et al. (9) was that the AR protein expression is regulated by ERß, although a definitive mechanism has not been described. Experiments using primary cultures of lizard testis cells (27) and Harderian gland cells (28) have demonstrated that estrogen also down-regulates AR mRNA expression. A recent report revealed a putative estrogen response element in the Hamster AR promoter mRNA (5'-untranslated region), although this consensus does not appear to be conserved in human or rodent AR mRNA (29). Clearly, the link between AR expression and estrogen exposure, at either the protein or mRNA level, requires further investigation. Nevertheless, the down-regulation of AR protein, and therefore androgen function by estrogen, may in part be responsible for the apoptotic response observed here. Interestingly, previous reports using ßERKO mice have described elevated expression of AR in the prostate (9, 10), but we did not observe this finding in the current study.

Estrogen acts by multiple signaling pathways in addition to the traditional steroid hormone receptor pathway including biological responses that are 1) ligand independent, where other factors such as growth factors stimulate ERE in the absence of ligand, or 2) ERE-independent actions, where the ligand/receptor complex targets genes by binding to other DNA-bound transcription factors forming a complex that alters downstream gene regulation independent of EREs (30). Nongenomic effects also occur, where estradiol activates putative membrane-associated binding sites, linked to intracellular signal transduction pathways to generate rapid tissue responses (30, 31, 32). In contrast to the genomic effects exerted by estrogens and ERs, nongenomic effects occur very rapidly, even seconds to minutes after estrogen exposure, to induce activation of intracellular second messengers such as calcium, nitric oxide formation, activation of kinases such as tyrosine kinases, protein kinase A, protein kinase C, ERK, and protein kinase B (33). Such effects have been described in neuronal, vascular, and bone systems (34). No evidence for nongenomic effects of estrogen in the induction of apoptosis in the prostate could be detected in this study using the membrane impermeable conjugate E2:BSA.

As a complementary, alternative approach to the use of ERKO mice to study ER-mediated events, we used the recently developed, novel ER subtype-selective ligands. The compound PPT is a potent ER{alpha} agonist that does not activate ERß. This results from the fact that it binds with high affinity and 400-fold preference to ER{alpha}, and demonstrates almost no binding for ERß (35, 36). In contrast, the compound DPN is a potency-selective agonist for ERß with a more than 70-fold higher binding affinity for ERß than ER{alpha} (37). These compounds have been used in vivo to examine ER-mediated responses in the mouse uterus (38) and pituitary (39, 40). In the current in vitro study, the ER subtype-selective ligands failed to induce apoptosis in the developing mouse prostate; however, differential biological responses on branching morphogenesis and cellular differentiation were observed; ER{alpha} agonist reduced prostate growth, disrupted the spatial organization of the gland, and altered cell differentiation in both epithelial and stromal compartments, whereas ERß appeared to cause dilation of the ducts as a result of enhance cellular differentiation and increased secretory activity. Future studies using these selective ligands will further our understanding of ER-mediated events in the prostate other than apoptosis.

The putative ERß-specific ligand is 3ßAdiol was hypothesized to be a preferred ligand for ERß in vivo (9, 10). 3ßAdiol is a 5{alpha}-dihydrotestosterone metabolite that competes with E2 for binding to ERß and elicits estrogenic responses (10, 41). In this study, we tested the effects of 3ßAdiol on the developing rodent prostate in vitro and failed to induce apoptosis. This result indicated that even if 3ßAdiol is the preferred ligand for ERß, it was unable to elicit an apoptotic response in the prostate gland.

Despite conflicting data fetal exposure to low doses of estrogens has been shown to induce permanent alterations in the prostate gland, including increased adult prostate weight (42, 43, 44). Neonatal exposure to high pharmacological doses of estrogens has also been shown to elicit effects on the gland, including permanent suppression of prostate growth and induction of epithelial hyperplasia in adulthood (25). Studies examining the effects of high doses of estrogens on the prostate have predominantly been carried out in vivo, where the direct effects of estrogens are confounded by the down-regulation of the hypothalamic-pituitary-gonadal axis after exogenous estrogen administration (1, 45). In these in vitro organ culture experiments, we used micromolar concentrations of E2, not unlike the pharmacological doses of estrogens given to rodents in developmental toxicology studies (46, 47) and men being treated for prostate cancer in the clinic (48). A previous report using MCF-7 breast cancer cells showed that, whereas lower concentrations stimulated cell proliferation, high concentrations (>10 µM) of E2 inhibited proliferation and induced apoptosis by non-ER-mediated actions (49), similar to that reported here. The mechanism by which high concentrations induce biological changes independent of ERs remains to be determined.

In summary, we demonstrated a direct effect of E2 on the prostate that includes the induction of apoptosis in rat and mouse organ cultures that was estrogen dependent, but not mediated through ER{alpha} or ERß, as determined using ERKO mice and ER-selective ligands. Although androgen levels were maintained in the culture media, AR protein expression was down-regulated, and may provide a possible explanation for the estrogen-induced apoptosis observed. Overall, this study failed to support the hypothesis that ERß directly mediates apoptosis in the developing prostate, but raises the possibility of antiproliferative actions in the prostate induced by high concentrations of estrogens through non-receptor-mediated pathways.


   Acknowledgments
 
We thank Hong Wang and Ann Davies (Monash Institute of Medical Research, Monash University) for technical assistance.


   Footnotes
 
First Published Online October 13, 2005

Abbreviations: 3ßAdiol, {alpha}-Androstane-3ß,17ß-diol; AR, androgen receptor; DPN, diaryl-proprionitrile; E2, 17ß-estradiol; ER, estrogen receptor; ERKO, ER knockout; {alpha}ERKO, mice deficient in ER{alpha}; ßERKO, mice deficient in ERß; H&E, hematoxylin and eosin; PPT, propyl pyrazole triol; T, testosterone; VP, ventral prostate; WT, wild type.

Received June 7, 2005.

Accepted for publication October 3, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS 1996 Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98:2558–2563[Medline]
  2. Prins GS, Birch L 1997 Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 138:1801–1809[Abstract/Free Full Text]
  3. Omoto Y, Imamov O, Warner M, Gustafsson JA 2005 Estrogen receptor {alpha} and imprinting of the neonatal mouse ventral prostate by estrogen. Proc Natl Acad Sci USA 102:1484–1489[Abstract/Free Full Text]
  4. Risbridger G, Wang H, Young P, Kurita T, Wang YZ, Lubahn D, Gustafsson JA, Cunha G, Wong YZ 2001 Evidence that epithelial and mesenchymal estrogen receptor-{alpha} mediates effects of estrogen on prostatic epithelium. Dev Biol 229:432–442[CrossRef][Medline]
  5. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS 2001 Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor {alpha}: studies with {alpha}ERKO and ßERKO mice. Cancer Res 61:6089–6097[Abstract/Free Full Text]
  6. Adams JY, Leav I, Lau KM, Ho SM, Pflueger SM 2002 Expression of estrogen receptor ß in the fetal, neonatal, and prepubertal human prostate. Prostate 52:69–81[CrossRef][Medline]
  7. Chang WY, Prins GS 1999 Estrogen receptor-ß: implications for the prostate gland. Prostate 40:115–124[CrossRef][Medline]
  8. Weihua Z, Warner M, Gustafsson J 2002 Estrogen receptor ß in the prostate. Mol Cell Endocrinol 193:1–5[CrossRef][Medline]
  9. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA 2001 A role for estrogen receptor ß in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98:6330–6335[Abstract/Free Full Text]
  10. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson JA 2004 Estrogen receptor ß regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 101:9375–9380[Abstract/Free Full Text]
  11. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M 2000 Effect of single and compound knockouts of estrogen receptors {alpha} (ER{alpha}) and ß (ERß) on mouse reproductive phenotypes. Development 127:4277–4291[Abstract]
  12. Couse JF, Curtis Hewitt S, Korach KS 2000 Receptor null mice reveal contrasting roles for estrogen receptor {alpha} and ß in reproductive tissues. J Steroid Biochem Mol Biol 74:287–296[CrossRef][Medline]
  13. Lau KM, LaSpina M, Long J, Ho SM 2000 Expression of estrogen receptor (ER)-{alpha} and ER-ß in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60:3175–3182[Abstract/Free Full Text]
  14. Montano MM, Jaiswal AK, Katzenellenbogen BS 1998 Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-{alpha} and estrogen receptor-ß. J Biol Chem 273:25443–25449[Abstract/Free Full Text]
  15. Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP 2000 Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology 141:3471–3477[Abstract/Free Full Text]
  16. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90:11162–11166[Abstract/Free Full Text]
  17. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor ß. Proc Natl Acad Sci USA 95:15677–15682[Abstract/Free Full Text]
  18. Lipschutz JH, Foster BA, Cunha GR 1997 Differentiation of rat neonatal ventral prostates grown in a serum-free organ culture system. Prostate 32:35–42[CrossRef][Medline]
  19. Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP 2002 Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 11:1689–1696[Abstract/Free Full Text]
  20. Imamov O, Lopatkin NA, Gustafsson JA 2004 Estrogen receptor ß in prostate cancer. N Engl J Med 351:2773–2774[Free Full Text]
  21. Prins GS, Marmer M, Woodham C, Chang W, Kuiper G, Gustafsson JA, Birch L 1998 Estrogen receptor-ß messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 139:874–883[Abstract/Free Full Text]
  22. Kyprianou N, Isaacs JT 1988 Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552–562[Abstract/Free Full Text]
  23. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW 2003 Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 54:212–219[CrossRef][Medline]
  24. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR 2001 Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8:192–200[CrossRef][Medline]
  25. Prins GS 1992 Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 130:3703–3714[Abstract/Free Full Text]
  26. Woodham C, Birch L, Prins GS 2003 Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology 144:4841–4850[Abstract/Free Full Text]
  27. Cardone A, Angelini F, Varriale B 1998 Autoregulation of estrogen and androgen receptor mRNAs and downregulation of androgen receptor mRNA by estrogen in primary cultures of lizard testis cells. Gen Comp Endocrinol 110:227–236[CrossRef][Medline]
  28. Esposito T, Astore E, Cardone A, Angelini F, Varriale B 2002 Regulation of androgen receptor mRNA expression in primary culture of Harderian gland cells: cross-talk between steroid hormones. Comp Biochem Physiol B Biochem Mol Biol 132:97–105[CrossRef][Medline]
  29. Varriale B, Esposito T 2005 The hamster androgen receptor promoter: a molecular analysis. J Steroid Biochem Mol Biol 94:103–110[CrossRef][Medline]
  30. Hall JM, Couse JF, Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:36869–36872[Free Full Text]
  31. Levin ER 1999 Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol Metab 10:374–377[CrossRef][Medline]
  32. Hewitt SC, Deroo BJ, Korach KS 2005 Signal transduction. A new mediator for an old hormone? Science 307:1572–1573[Abstract/Free Full Text]
  33. Luconi M, Forti G, Baldi E 2002 Genomic and nongenomic effects of estrogens: molecular mechanisms of action and clinical implications for male reproduction. J Steroid Biochem Mol Biol 80:369–381[CrossRef][Medline]
  34. Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12:152–156[CrossRef][Medline]
  35. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA 2000 Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-{alpha}-selective agonists. J Med Chem 43:4934–4947[CrossRef][Medline]
  36. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS 2000 Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-{alpha} and estrogen receptor-ß: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141:3534–3545[Abstract/Free Full Text]
  37. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA 1999 Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11, 12-tetrahydrochrysenes. J Med Chem 42:2456–2468[CrossRef][Medline]
  38. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS 2003 Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) {alpha} activity by ERß in the uterus. Endocrinology 144:3159–3166[Abstract/Free Full Text]
  39. Tena-Sempere M, Navarro VM, Mayen A, Bellido C, Sanchez-Criado JE 2004 Regulation of estrogen receptor (ER) isoform messenger RNA expression by different ER ligands in female rat pituitary. Biol Reprod 70:671–678[Abstract/Free Full Text]
  40. Sanchez-Criado JE, Martin De Las Mulas J, Bellido C, Tena-Sempere M, Aguilar R, Blanco A 2004 Biological role of pituitary estrogen receptors ER{alpha} and ERß on progesterone receptor expression and action and on gonadotropin and prolactin secretion in the rat. Neuroendocrinology 79:247–258[CrossRef][Medline]
  41. Voigt KD, Bartsch W 1986 Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25:749–757[CrossRef][Medline]
  42. Nonneman DJ, Ganjam VK, Welshons WV, vom Saal FS 1992 Intrauterine position effects on steroid metabolism and steroid receptors of reproductive organs in male mice. Biol Reprod 47:723–729[Abstract]
  43. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV 1997 Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94:2056–2061[Abstract/Free Full Text]
  44. Timms BG, Petersen SL, vom Saal FS 1999 Prostate gland growth during development is stimulated in both male and female rat fetuses by intrauterine proximity to female fetuses. J Urol 161:1694–1701[CrossRef][Medline]
  45. Cook JC, Johnson L, O’Connor JC, Biegel LB, Krams CH, Frame SR, Hurtt ME 1998 Effects of dietary 17ß-estradiol exposure on serum hormone concentrations and testicular parameters in male Crl:CD BR rats. Toxicol Sci 44:155–168[Abstract/Free Full Text]
  46. Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, Vom Saal FS 2005 Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 102:7014–7019[Abstract/Free Full Text]
  47. Prins GS 1997 Developmental estrogenization of the prostate gland. In: Naz R, ed. Prostate basic and clinical aspects. New York: CRC Press; 245–263
  48. Siddiqui K, Abbas F, Biyabani SR, Ather MH, Talati J 2004 Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer. J Pak Med Assoc 54:445–447[Medline]
  49. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS 2002 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors {alpha} and ß. Cancer Res 62:3691–3697[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Zarate, G. Jaita, V. Zaldivar, D. B. Radl, G. Eijo, J. Ferraris, D. Pisera, and A. Seilicovich
Estrogens exert a rapid apoptotic action in anterior pituitary cells
Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E664 - E671.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Chen, I. Hsu, A. Wolfe, S. Radovick, K. Huang, S. Yu, C. Chang, E. M. Messing, and S. Yeh
Defects of Prostate Development and Reproductive System in the Estrogen Receptor-{alpha} Null Male Mice
Endocrinology, January 1, 2009; 150(1): 251 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. A. Harris
Estrogen Receptor-{beta}: Recent Lessons from in Vivo Studies
Mol. Endocrinol., January 1, 2007; 21(1): 1 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
K. Dahlman-Wright, V. Cavailles, S. A. Fuqua, V. C. Jordan, J. A. Katzenellenbogen, K. S. Korach, A. Maggi, M. Muramatsu, M. G. Parker, and J.-A. Gustafsson
International Union of Pharmacology. LXIV. Estrogen Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 773 - 781.
[Full Text] [PDF]

Home page
 J EndocrinolHome page
A Tivesten, E Bollano, H C Nystrom, C Alexanderson, G Bergstrom, and A Holmang
Cardiac concentric remodelling induced by non-aromatizable (dihydro-)testosterone is antagonized by oestradiol in ovariectomized rats.
J. Endocrinol., June 1, 2006; 189(3): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. S. Bhattacharyya, A. V. Krishnan, S. Swami, and D. Feldman
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Mol. Cancer Ther., June 1, 2006; 5(6): 1539 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Zhang and B. C. Paria
Importance of Uterine Cell Death, Renewal, and Their Hormonal Regulation in Hamsters that Show Progesterone-Dependent Implantation
Endocrinology, May 1, 2006; 147(5): 2215 - 2227.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, R. A
Right arrow Articles by Risbridger, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, R. A
Right arrow Articles by Risbridger, G. P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals